CDK9 and atherosclerosis: Treatment with CDK9 inhibitor LDC000067 dramatically reduced hyperlipidemia-induced inflammation and phenotypic switching of VSMCs and ultimately prevented atherosclerosis progress without changing serum lipid levels, indicating that CDK9 may be a new target for the prevention of atherosclerosis.